Directorio de personas
Juan Verdaguer Autonell

Juan Verdaguer Autonell

Grado: Doctor/a

973 702 210
joan.verdaguer(ELIMINAR)@udl.cat

Grupos

Publicaciones

  • Sisó, P; de la Rosa, I; Rios, C; Panosa, A; Verdaguer, J; Martí, R; Macià, A

    Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    Star Protocols 4 102690-102690. .

    [doi:10.1016/j.xpro.2023.102690]

  • Corral-Pujol, M; Arpa, B; Rosell-Mases, E; Egia-Mendikute, L; Mora, C; Stratmann, T; Sanchez, A; Casanovas, A; Esquerda, JE; Mauricio, D; Vives-Pi, M; Verdaguer, J

    NOD mouse dorsal root ganglia display morphological and gene expression defects before and during autoimmune diabetes development.

    Frontiers in Endocrinology 14 1176566-1176566. .

    [doi:10.3389/fendo.2023.1176566]

  • Almenara-Fuentes L; Rodriguez-Fernandez S; Rosell-Mases E; Kachler K; You A; Salvado M; Andreev D; Steffen U; Bang H; Bozec A; Schett G; Le Panse R; Verdaguer J; Dalmases M; Rodriguez-Vidal S; Barneda-Zahonero B; Vives-Pi M

    A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens.

    Nanomedicine-Nanotechnology Biology and Medicine 48 102635-102635. .

    [doi:10.1016/j.nano.2022.102635]

  • Rosell-Mases E.; Santiago A.; Corral-Pujol M.; Yáñez F.; Varela E.; Egia-Mendikute L.; Arpa B.; Cosovanu C.; Panosa A.; Serrano-Gómez G.; Mora C.; Verdaguer J.; Manichanh C.

    Mutual modulation of gut microbiota and the immune system in type 1 diabetes models

    Nature Communications 14 7770-7770. .

    [doi:10.1038/s41467-023-43652-x]

  • Sala E; Vived C; Luna J; Saavedra-Ávila NA; Sengupta U; Castaño AR; Villar-Pazos S; Haba L; Verdaguer J; Ropero AB; Stratmann T; Pizarro J; Vázquez-Carrera M; Nadal A; Lahti JM; Mora C

    CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model.

    Frontiers in Immunology 12 634797-634797. .

    [doi:10.3389/fimmu.2021.634797]

  • Villalba, A; Rodriguez-Fernandez, S; Perna-Barrull, D; Ampudia, RM; Gomez-Munoz, L; Pujol-Autonell, I; Aguilera, E; Coma, M; Cano-Sarabia, M; Vazquez, F; Verdaguer, J; Vives-Pi, M

    Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.

    Frontiers in Endocrinology 11 258-258. .

    [doi:10.3389/fendo.2020.00258]

  • Garcia-de-la-Fuente, MR; Santacana, M; Verdaguer, J; Vilardell, F; Gari, E; Casanova, JM

    Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.

    Australasian Journal of Dermatology 61 200-207. .

    [doi:10.1111/ajd.13229]

  • Egia-Mendikute, L; Arpa, B; Rosell-Mases, E; Corral-Pujol, M; Carrascal, J; Carrillo, J; Mora, C; Chapman, H; Panosa, A; Vives-Pi, M; Stratmann, T; Serreze, D; Verdaguer, J

    B-Lymphocyte Phenotype Determines T-Lymphocyte Subset Differentiation in Autoimmune Diabetes

    Frontiers in Immunology 10 1732-1732. .

    [doi:10.3389/fimmu.2019.01732]

  • Mollo, A; Hernandez, M; Marsal, JR; Esquerda, A; Rius, F; Blanco-Vaca, F; Verdaguer, J; Pozzilli, P; de Leiva, A; Mauricio, D

    Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain (vol 29, pg 446, 2013)

    DIABETES-METABOLISM RESEARCH AND REVIEWS 34 446-446. .

    [doi:10.1002/dmrr.3017]

  • Izquierdo, C; Ortiz, AZ; Presa, M; Malo, S; Montoya, A; Garabatos, N; Mora, C; Verdaguer, J; Stratmann, T

    Treatment of T1D via optimized expansion of antigen- specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers

    SCIENTIFIC REPORTS 8 8106-8106. .

    [doi:10.1038/s41598-018-26161-6]

  • Rodriguez-Fernandez, S; Pujol-Autonell, I; Brianso, F; Perna-Barrull, D; Cano-Sarabia, M; Garcia-Jimeno, S; Villalba, A; Sanchez, A; Aguilera, E; Vazquez, F; Verdaguer, J; Maspoch, D; Vives-Pi, M

    Phosphatidylserine-liposomes Promote Tolerogenic Features on Dendritic cells in human Type 1 Diabetes by apoptotic Mimicry

    Frontiers in Immunology 9 253-253. .

    [doi:10.3389/fimmu.2018.00253]

  • Verdaguer, J

    The specific immunotherapy of autoimmune diseases through the nanomedicine

    ENDOCRINOLOGIA Y NUTRICION 63 437-439. .

    [doi:10.1016/j.endonu.2016.05.003]

Proyectos

  • Estudio del impacto generado por modificaciones en la microbiota intestinal sobre la actividad del sistema inmune en el modelo murino NOD de diabetes autoinmune.
  • OncoNeoVac, un nuevo enfoque inmunoterapéutico para el tratamiento del melanoma.
  • INVESTIGO 2022: Grup de Recerca en Immunologia i Metabolisme (GRIM)
  • Modelación de la microbiota intestinal en las etapas iniciales del desarrollo de la diabetes autoinmune en el ratón NOD, modelo de la diabetes tipo 1 humana.
  • Estudi de l'efecte adjuvant de DIF-P en una vacuna antigripal
  • Linfocitos T y B anti-periferina y anti-cromogranina T and B lymphocyte durante el desarrollo de la Diabetes Mellitus Tipo 1 (APACT1D)
  • Linfocitos B y T autoreactivos en la diabetes del tipo 1: Análisis funcional y desarrollo de estrategias de tratamiento (BATINT1D)
  • CARACTERIZACIÓN DE LA RESPUESTA DE LINFOCITOS B AUTOREACTIVOS CONTRA UN NUEVO AUTOANTIGENO DE 90 KDA ESPECIFICO DE CELULAS BETA PANCREATICAS DURANTE EL DESARROLLO DE LA DIABETES TIPO 1
  • IDENTIFICACIO DEL NOU AUTOANTIGEN ICA85 I CARACTERITZACIO DE LA RESPOSTA AUTOINMUNITARIA CONTRA AQUEST EN PACIENTS AMB DIABETIS TIPUS 1